Below are the most recent publications written about "Receptors, Mineralocorticoid" by people in Profiles.
-
Ajibade TO, Awodele OA, Tijani MO, Adejumobi OA, Adetona MO, Oyagbemi AA, Adedapo AD, Omobowale TO, Aro AO, Ola-Davies OE, Saba AB, Adedapo AA, Nkadimeng SM, McGaw LJ, Kayoka-Kabongo PN, Oguntibeju OO, Yakubu MA. L-arginine and lisinopril supplementation protects against sodium fluoride-induced nephrotoxicity and hypertension by suppressing mineralocorticoid receptor and angiotensin-converting enzyme 3 activity. Environ Sci Pollut Res Int. 2023 Feb; 30(9):23263-23275.
-
Wang Y, Wang J, Yang R, Wang P, Porche R, Kim S, Lutfy K, Liu L, Friedman TC, Jiang M, Liu Y. Decreased 11?-Hydroxysteroid Dehydrogenase Type 2 Expression in the Kidney May Contribute to Nicotine/Smoking-Induced Blood Pressure Elevation in Mice. Hypertension. 2021 06; 77(6):1940-1952.
-
Oyagbemi AA, Bolaji-Alabi FB, Ajibade TO, Adejumobi OA, Ajani OS, Jarikre TA, Omobowale TO, Ola-Davies OE, Soetan KO, Aro AO, Emikpe BO, Saba AB, Adedapo AA, Oyeyemi MO, Nkadimeng SM, Kayoka-Kabongo PN, McGaw LJ, Oguntibeju OO, Yakubu MA. Novel antihypertensive action of rutin is mediated via inhibition of angiotensin converting enzyme/mineralocorticoid receptor/angiotensin 2 type 1 receptor (ATR1) signaling pathways in uninephrectomized hypertensive rats. J Food Biochem. 2020 12; 44(12):e13534.
-
Oyagbemi AA, Omobowale TO, Adejumobi OA, Owolabi AM, Ogunpolu BS, Falayi OO, Hassan FO, Ogunmiluyi IO, Asenuga ER, Ola-Davies OE, Soetan KO, Saba AB, Adedapo AA, Nkadimeng SM, McGaw LJ, Oguntibeju OO, Yakubu MA. Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway. Eur J Pharmacol. 2020 Aug 05; 880:173142.
-
Torres-Rever?n A, Rana M, Gorabi V, Rivera-Lopez LL, Appleyard CB. Short treatment with antalarmin alters adrenal gland receptors in the rat model of endometriosis. PLoS One. 2020; 15(1):e0227456.
-
Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Curr Hypertens Rep. 2018 03 19; 20(3):23.
-
Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.
-
Guichard JL, Clark D, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag. 2013; 9:321-31.
-
Hartmann J, Wagner KV, Liebl C, Scharf SH, Wang XD, Wolf M, Hausch F, Rein T, Schmidt U, Touma C, Cheung-Flynn J, Cox MB, Smith DF, Holsboer F, M?ller MB, Schmidt MV. The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology. 2012 Jan; 62(1):332-9.
-
De Mello WC, Gerena Y. Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. Regul Pept. 2008 Nov 29; 151(1-3):54-60.